When was Enodia Therapeutics founded?

Enodia Therapeutics was founded in 2025 and raised its 1st funding round 1 year after it was founded.

Where is Enodia Therapeutics located?

Enodia Therapeutics is headquartered in Paris, France.

How many employees does Enodia Therapeutics have?

As of Sep 30, 2026, the latest employee count at Enodia Therapeutics is 16.

Is Enodia Therapeutics a funded company?

Enodia Therapeutics is a funded company, having raised a total of $***** in its 1st and only funding round, a Seed round on Jan 08, 2026.

When was the latest funding round of Enodia Therapeutics?

Enodia Therapeutics' latest funding was a $***** Seed round on Jan 08, 2026, with participation from 9 investors. Its primary sector is Immunology. In France, the Immunology sector has seen $195M in funding in 2026 to date.

Where does Enodia Therapeutics rank among its competitors?

Enodia Therapeutics ranks 154th amongst 436 active competitors, of which 136 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Enodia Therapeutics, which secured $25M in Jan, 2026.

Who are the top competitors of Enodia Therapeutics?

Enodia Therapeutics' top competitors include Biogen, BeiGene and argenx. Among them, Enodia Therapeutics secured the most recent funding round in January, 2026.

Enodia Therapeutics - 2026 Company Profile, Funding & Competitors

Enodia Therapeutics is a seed company based in Paris (France), founded in 2025. It operates as a Developer of small-molecule therapies for inflammatory and autoimmune diseases. Enodia Therapeutics has raised $25M in funding from investors like Elaia, Pfizer and Bpifrance. The company has 436 active competitors, including 136 funded and 119 that have exited. Its top competitors include companies like Biogen, BeiGene and argenx.

Company Details

Developer of small-molecule therapies for inflammatory and autoimmune diseases. The company specializing in small-molecule therapies for targeted protein degradation at the point of synthesis via the Sec61 translocon. The company targets disease-driving secreted and membrane proteins, primarily for immuno-inflammatory and autoimmune disorders, with expansion potential into oncology and viral infections.

Key Metrics

Founded Year

2025

Location

Paris, France

Stage

Seed

Total Funding

$25M in 1 round

Latest Funding Round

Seed, Jan 08, 2026, $*****

Investors

Elaia & 9 more

Ranked

154^th among 436 active competitors

Employee Count

16 as on Sep 30, 2026

Similar Companies

Biogen & 506 more

View Enodia Therapeutics' full profile

Enodia Therapeutics has raised a total funding of $25M over 1 round. Its latest funding round was a Seed round on Jan 08, 2026 for $*****. 9 investors participated in its latest round. Enodia Therapeutics has 10 institutional investors.

Here is the list of recent funding rounds of Enodia Therapeutics:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 08, 2026	6540012	Seed	7262833	9302718	7567558	8720751

Access funding benchmarks and valuations. Sign up today!

View details of Enodia Therapeutics's funding rounds and investors

Enodia Therapeutics' employee count trend

Enodia Therapeutics has 16 employees as of Sep 26. Here is Enodia Therapeutics's employee count trend over the years:

Employee count trend for Enodia Therapeutics

Uncover Enodia Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Enodia Therapeutics include Biogen, BeiGene and argenx. Here is the list of Top 10 competitors of Enodia Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Digital Pharma Lab & 11 others	78/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	77/100
3rd	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, Seventure Partners ... & 21 others	76/100
4th	BioNTech 2008, Mainz (Germany), Public	Developer of immunotherapeutics for the treatment of cancer and other diseases	$861M	Fidelity Investments, Redmile Group & 28 others	71/100
5th	Immunocore 2008, Abingdon (United Kingdom), Public	Developer of bispecific T cell receptor therapies for human diseases	$601M	General Atlantic, BlackRock & 50 others	70/100
6th	Ionis 1989, United States, Public	Developer of RNA-targeted medicines for various diseases	-	BB Biotech, Ojp & 1 others	69/100
7th	DBV Technologies 2002, Bagneux (France), Public	Developer of products for the treatment of various kinds of food allergies	$68.9M	Sofinnova Partners, Lundbeck Foundation & 16 others	68/100
8th	Vera Therapeutics 2016, San Francisco (United States), Public	Developer of therapeutic solutions for the treatment of immunological and inflammatory diseases	$117M	Abingworth, Fidelity Investments & 13 others	68/100
9th	Cabaletta Bio 2017, Radnor (United States), Public	Developer of CAAR T cells for B cell-mediated autoimmune diseases	$88.3M	Boxer Capital, Redmile Group & 6 others	68/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	68/100
154th	Enodia Therapeutics 2025, Paris (France), Seed	Developer of small-molecule therapies for inflammatory and autoimmune diseases	$25M	Mission BioCapital, Pfizer & 8 others	39/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Enodia Therapeutics's competitors? Click here to see the top ones

Enodia Therapeutics has made no investments or acquisitions yet.

Here is the latest report on Enodia Therapeutics's sector:

Free

Immunology - Sector Report

Edition: September, 2026 (67 Pages)

View all reports related to Enodia Therapeutics

Media has covered Enodia Therapeutics for a total of 13 events in the last 1 year, 4 of them have been about company updates and 3 about partnerships.